Targeted Cellular Technology

Targeted Cellular Technology® is a patented formulation that allows reduced concentrations of amino acids to promote the production of neurotransmitters in the body. Neurotransmitter depletion is involved in a wide variety of disease states including pain syndromes, fibromyalgia syndromes, neurotoxicity syndromes, sleep disorders, asthma, hypertension, metabolic syndrome and obesity. Amino acids are the precursors from which the body produces neurotransmitters, critical chemical messengers that regulate most bodily functions. The ability to increase neurotransmitter production results in pain control, improved sleep quality, more acute cognitive function, blood pressure regulation, bronchodilation, appetite regulation and amelioration of symptoms associated with complex medical syndromes with few or no side effects.

Targeted Cellular Technology® is a five-component process that allows milligram quantities of neurotransmitter precursors to enter the neurons and stimulate the production of neurotransmitters. This unique and patented process includes a neurotransmitter precursor, an uptake stimulator, a neuron activator, an adenosine brake inhibitor, and an attenuation releaser. Clinical evidence indicates that the use of the Targeted Cellular Technology® process can prevent the development of tolerance. Unlike pharmaceutical agents that lose their effectiveness over time, Targeted Cellular Technology® allows Medical Foods to maintain effectiveness without attenuation.

The Targeted Cellular Technology® platform allows for reduced concentrations in the milligram range to stimulate neurotransmitter function compared to previous amino acid based systems that required gram quantities to elicit a physiological response and did not address the attenuation problem. The Company's products can address multiple neurotransmitters simultaneously, compared to pharmaceuticals that generally can only address a single neurotransmitter site. Thus, nutrient based therapeutic systems can be developed that address the distinctive nutritional requirements of a particular disease, based on recognized scientific principles, established by medical evaluation. The Company has developed products that address disease states with documented nutritional requirements that include obesity, metabolic syndrome, sleep disorders, pain syndromes, depression, anxiety, asthma, hypertension and viral infections.

The Importance of Neurotransmitters

The nutrient requirements in disease states involve the amino acids that function as neurotransmitters in the transmission of cell-to-cell signals, utilized for synthesis of neurotransmitters in this process. The concept that nutrient requirements are modified in disease has long been recognized, and is supported by studies that have shown changes in plasma, urinary, and tissue levels of nutrients associated with changes in physiological endpoints reflective of the disease pathology. These requirements can be estimated by determining the level of intake at which a physiological response is normalized, indicating that the balance between intake and metabolic demand has been restored. For example, in pain syndromes, improvement in perceived intensity of back pain following consumption of supplemental amounts of 5-hydroxytryptophan, arginine, and glutamine in a specific formulation suggests that an additional and specific allowance for tryptophan, arginine, and glutamate is needed by individuals with pain syndromes.